Literature DB >> 26764220

Non-coding RNAs as modulators of the cardiac fibroblast phenotype.

Maria-Teresa Piccoli1, Christian Bär1, Thomas Thum2.   

Abstract

Cardiac fibroblasts represent one of the most frequent cell type in the heart of rodents and humans and alterations of their phenotype have a great impact on cardiac function. Due to aging, ischemic injuries, valvular dysfunctions, hypertension and aortic stenosis, multiple signals trigger the accumulation of extracellular matrix in the cardiac interstitium and perivascular space, leading to structural and functional detrimental changes in the heart. Cardiac fibroblasts are the principal orchestrators of matrix formation and degradation and indirectly regulate cardiac hypertrophy and inflammation. Understanding the molecular bases of their action could provide tools for the treatment of cardiac remodeling. This review summarizes recent evidences on non-coding RNAs, including microRNAs and long non-coding RNAs that modulate the phenotype of cardiac fibroblasts and may serve in the future as targets for novel therapeutic strategies against cardiac fibrosis.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac fibrosis; Heart failure; Long noncoding RNA; microRNA

Mesh:

Substances:

Year:  2016        PMID: 26764220     DOI: 10.1016/j.yjmcc.2015.12.023

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  21 in total

1.  The long noncoding RNA Wisper controls cardiac fibrosis and remodeling.

Authors:  Rudi Micheletti; Isabelle Plaisance; Brian J Abraham; Alexandre Sarre; Ching-Chia Ting; Michael Alexanian; Daniel Maric; Damien Maison; Mohamed Nemir; Richard A Young; Blanche Schroen; Arantxa González; Samir Ounzain; Thierry Pedrazzini
Journal:  Sci Transl Med       Date:  2017-06-21       Impact factor: 17.956

2.  Interleukin-10 Inhibits Bone Marrow Fibroblast Progenitor Cell-Mediated Cardiac Fibrosis in Pressure-Overloaded Myocardium.

Authors:  Suresh K Verma; Venkata N S Garikipati; Prasanna Krishnamurthy; Sarah M Schumacher; Laurel A Grisanti; Maria Cimini; Zhongjian Cheng; Mohsin Khan; Yujia Yue; Cindy Benedict; May M Truongcao; Joseph E Rabinowitz; David A Goukassian; Douglas Tilley; Walter J Koch; Raj Kishore
Journal:  Circulation       Date:  2017-06-30       Impact factor: 29.690

Review 3.  Role of circulating factors in cardiac aging.

Authors:  Antonio Cannatà; Gabriella Marcon; Giovanni Cimmino; Luca Camparini; Giulio Ciucci; Gianfranco Sinagra; Francesco S Loffredo
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

4.  miR-33 Regulation of Adaptive Fibrotic Response in Cardiac Remodeling.

Authors:  Xinbo Zhang; Carlos Fernández-Hernando
Journal:  Circ Res       Date:  2017-03-03       Impact factor: 17.367

Review 5.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

Review 6.  Diabetic fibrosis.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-12-28       Impact factor: 5.187

7.  SGLT2 promotes cardiac fibrosis following myocardial infarction and is regulated by miR-141.

Authors:  Gang Li; Congchun Zhao; Shanhua Fang
Journal:  Exp Ther Med       Date:  2021-05-03       Impact factor: 2.447

Review 8.  Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches.

Authors:  Begoña López; Susana Ravassa; María U Moreno; Gorka San José; Javier Beaumont; Arantxa González; Javier Díez
Journal:  Nat Rev Cardiol       Date:  2021-02-10       Impact factor: 32.419

9.  Elevated IgE promotes cardiac fibrosis by suppressing miR-486a-5p.

Authors:  Hongmei Zhao; Hongqin Yang; Chi Geng; Yang Chen; Yaqin Tang; Zhiwei Li; Junling Pang; Ting Shu; Yu Nie; Yongshuo Liu; Kegang Jia; Jing Wang
Journal:  Theranostics       Date:  2021-06-05       Impact factor: 11.556

Review 10.  Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.